TY - JOUR
T1 - The role of PCA3 testing in patients with a raised prostate-specific antigen level after greenlight photoselective vaporization of the prostate
AU - Henderson, James
AU - Ghani, Khurshid R.
AU - Cook, Joanne
AU - Fahey, Michael
AU - Schalken, Jack
AU - Thilagarajah, Ranjan
PY - 2010/11/1
Y1 - 2010/11/1
N2 - Background and Purpose: Greenlight® photoselective vaporization of the prostate (PVP) is an effective method for treating men with lower urinary tract symptoms. A rise in prostate specific antigen (PSA) levels, however, may be noticed in some patients during follow-up. The aim of this study was to determine whether the prostate cancer gene 3 (PCA3) urinary test would help identify patients who were in need of a prostate biopsy. Patients and Methods: The PSA of all patients undergoing PVP were analyzed. Patients with an elevated (above reference range) or rising PSA level (defined as >0.75ng/mL/year if the PSA was between 4.1 and 10 or a doubling time of less than 2 years) were offered a transrectal ultrasonography (TRUS) guided prostate biopsy. Before the biopsy procedure, all patients had a PCA3 test. The relationships between PSA, PCA3, and TRUS prostate biopsy findings were analyzed to determine sensitivity and specificity for the PCA3 test in this setting. Results: 50 patients were identified. The mean age was 69.97 (range 57-83) years. The mean PSA level was 10.1ng/mL (range 3.03-44.2ng/mL). Six patients were found to have prostate cancer. Of those, five patients had a positive PCA3 test. One patient had a negative PCA3 test but positive biopsy findings. This gives a sensitivity of 83.3%, and a positive predictive value of 21.7%. The negative predictive value was 96%. Conclusion: The results suggest that a negative PCA3 test in our group of patients is a good predictor of negative biopsy results. The low positive predictive value may be an artefact of the group size. This will need further investigation and greater patient numbers to determine.
AB - Background and Purpose: Greenlight® photoselective vaporization of the prostate (PVP) is an effective method for treating men with lower urinary tract symptoms. A rise in prostate specific antigen (PSA) levels, however, may be noticed in some patients during follow-up. The aim of this study was to determine whether the prostate cancer gene 3 (PCA3) urinary test would help identify patients who were in need of a prostate biopsy. Patients and Methods: The PSA of all patients undergoing PVP were analyzed. Patients with an elevated (above reference range) or rising PSA level (defined as >0.75ng/mL/year if the PSA was between 4.1 and 10 or a doubling time of less than 2 years) were offered a transrectal ultrasonography (TRUS) guided prostate biopsy. Before the biopsy procedure, all patients had a PCA3 test. The relationships between PSA, PCA3, and TRUS prostate biopsy findings were analyzed to determine sensitivity and specificity for the PCA3 test in this setting. Results: 50 patients were identified. The mean age was 69.97 (range 57-83) years. The mean PSA level was 10.1ng/mL (range 3.03-44.2ng/mL). Six patients were found to have prostate cancer. Of those, five patients had a positive PCA3 test. One patient had a negative PCA3 test but positive biopsy findings. This gives a sensitivity of 83.3%, and a positive predictive value of 21.7%. The negative predictive value was 96%. Conclusion: The results suggest that a negative PCA3 test in our group of patients is a good predictor of negative biopsy results. The low positive predictive value may be an artefact of the group size. This will need further investigation and greater patient numbers to determine.
UR - http://www.scopus.com/inward/record.url?scp=78149401863&partnerID=8YFLogxK
U2 - 10.1089/end.2010.0196
DO - 10.1089/end.2010.0196
M3 - Article
AN - SCOPUS:78149401863
SN - 0892-7790
VL - 24
SP - 1821
EP - 1824
JO - Journal of Endourology
JF - Journal of Endourology
IS - 11
ER -